Ligand Pharmaceuticals Inc(LGND) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | RUT | P/E | 32.96 | EPS (ttm) | 9.35 | Insider Own | 2.42% | Shs Outstand | 19.9M | Perf Week | 3.71% |
| Market Cap | 6.15B | Forward P/E | 25.44 | EPS next Y | 29.65% | Insider Trans | -15.82% | Shs Float | 19.4M | Perf Month | 2.25% |
| Enterprise Value | 5.92B | PEG | 1.18 | EPS next Q | 2.33 | Inst Own | 114.64% | Short Float | 13.77% | Perf Quarter | 4.06% |
| Income | 0.20B | P/S | 21.16 | EPS this Y | 14.97% | Inst Trans | 8.72% | Short Ratio | 10.84 | Perf Half Y | 27.51% |
| Sales | 0.29B | P/B | 6.35 | EPS next 5Y | 21.49% | ROA | 12.58% | Short Interest | 2.68M | Perf YTD | 63.06% |
| Book/sh | 48.57 | P/C | 4.53 | EPS past 3/5Y | - | ROE | 21.96% | 52W High | -5.61% ($326.63) | Perf Year | 64.88% |
| Cash/sh | 68.09 | P/FCF | 46.75 | Sales past 3/5Y | 10.96% 7.54% | ROIC | 9.4% | 52W Low | 75.28% ($175.89) | Perf 3Y | 503.8% |
| Dividend Est. | - | EV/EBITDA | 44.07 | EPS Y/Y TTM | 350.86% | Gross Margin | 84.28% | Volatility(W/M) | 3.7% 3.66% | Perf 5Y | 240.78% |
| Dividend TTM | - | EV/Sales | 20.38 | Sales Y/Y TTM | 54.89% | Oper. Margin | 34.45% | ATR (14) | 10.45 | Perf 10Y | 402.13% |
| Dividend Ex-Date | 2010/7/2 | Quick Ratio | 30.96 | EPS Q/Q | 813.4% | Profit Margin | 67.88% | RSI (14) | 55.48 | Recom | 1.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 31.18 | Sales Q/Q | 33.73% | SMA20 | 1.68% ($303.21) | Beta | 1.2 | Target Price | $354.73 |
| Payout | - | Debt/Eq | 1.17 | Earnings | 2026/10/29 | SMA50 | 4.82% ($294.12) | Rel Volume | 0.79 | Prev Close | $303.53 |
| Employees | 47 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 17.92% 3.9% | SMA200 | 23.17% ($250.3) | Avg Volume(3M) | 0.25M | Price | $308.3 |
| IPO | 1992/11/18 | Option/Short | Yes/Yes | Trades | 5748 | Volume | 194,842 | Change | 1.57% |
💊 A biopharmaceutical royalty company built on a pharmaceutical royalty and formulation technology platform. Rather than selling its own drugs directly, its core model is an asset-light approach that provides technology and capital to other pharmaceutical companies for their new drug development and commercialization, in return for royalties. It holds multiple royalty assets along with formulation technology platforms such as Captisol.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
Next earnings report: October 29
2 days to go.
LGND makes money exceptionally well
Of every $100 in sales, $34.45 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +15.0% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,544. Peers typically go for $2,544. Compared with its own 4-year average, it is 13% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +240.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 114.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #41 of 594 in the industry
Based on market cap of $6B.
IOVA#39 Iovance Biotherapeutics Inc $6B PER - 
RYTM#40 Rhythm Pharmaceuticals Inc $6B PER - LGND#41 Ligand Pharmaceuticals Inc $6B PER 33.0 
ORKA#42 Oruka Therapeutics Inc $6B PER - 
IMVT#43 Immunovant Inc $6B PER - 
FAQ
What kind of company is LGND?
LGND belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LGND?
The market cap of LGND is approximately $6.1B, ranking 1,188 within its sector.
What is the P/E ratio of LGND?
LGND has a P/E ratio of approximately 33.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LGND?
LGND has recorded a 52-week high of $326.63 and a low of $175.89.
